Linked Life Data

19615993

Source:http://linkedlifedata.com/resource/pubmed/id/19615993

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-3
pubmed:dateCreated
2009-8-17
pubmed:abstractText
Endostatin is an endogenous inhibitor of angiogenesis and has been shown to exhibit potent inhibitory activity in certain mice tumor models. In this study, a treatment strategy of combining recombinant human endostatin (rhEndostatin) and chemotherapeutics was implemented to evaluate the therapeutic efficacy of rhEndostatin against solid tumors. The antitumor effect of rhEndostatin in combination with several chemotherapeutic drugs, e.g., 5-fluorouracil, cyclophosphamide, methotrexate, and mitomycin C, on human QGY liver tumor and mice H22 liver tumor was compared with that of rhEndostatin treatment alone. The results showed that the combination of rhEndostatin and chemotherapeutic drugs resulted in a more potent inhibition of tumor growth. The potential advantages of rhEndostatin plus tumor chemotherapy provide a basis for further clinical trials of rhEndostatin.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1879-0712
pubmed:author
pubmed:issnType
Electronic
pubmed:day
1
pubmed:volume
617
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
23-7
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Therapeutic efficacy of recombinant human endostatin combined with chemotherapeutics in mice-transplanted tumors.
pubmed:affiliation
Department of Biological Science and Technology and State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, China.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't